Myeloma Cure Summit: Definitions, Metrics, and Milestones

A central goal for this meeting is to establish a working consensus on the definition of “cure” in myeloma with international thought leaders on myeloma. Dedicated sessions will evaluate key parameters including depth and durability of minimal residual disease (MRD) negativity, advanced imaging, mass spectrometry, immune reconstitution, time off therapy, restoration of normal function, and potential reversion to an MGUS-like state. These metrics will be discussed under the guidance of leading investigators and clinicians.

Preliminary Program